Diffuse large B-cell lymphoma: open trials in China

• NCT07749365

  Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL

  Trial Treatment · Phase 2 · The First Affiliated Hospital of Xiamen University

  The First Affiliated hospital of Xiamen University, Xiamen

  Registry updated 2026-08-06

• NCT07712588

  Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)

  Trial Treatment · Phase 2/3 · Dizal Pharmaceuticals

  Hunan Cancer Hospital, Changsha · Chongqing University Cancer Hospital, Chongqing · Harbin Medical University Cancer Hospital, Harbin · Cancer Hospital of Shandong Frist Medical University, Jinan · Shanghai Jiao Tong University School of Medicine - Ruijin Hospital, Shanghai

  Registry updated 2026-08-05

• NCT06570447

  Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

  Trial Treatment · Phase 2 · Tianjin Medical University Cancer Institute and Hospital

  Tianjin Medical University Cancer Insititute & Hospital, Tianjin

  Registry updated 2026-08-03

• NCT07609862

  A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies

  Trial Treatment · Phase 1/2 · Guangzhou Lupeng Pharmaceutical Company LTD.

  Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

  Registry updated 2026-07-30

• NCT07397832

  CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL

  Trial Treatment · Phase 2 · Tianjin Medical University Cancer Institute and Hospital

  Tianjin Medical University Cancer Insititute & Hospital, Tianjin

  Registry updated 2026-07-29

• NCT07494565

  Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL

  Trial Treatment · Phase 2 · Sun Yat-sen University

  Sun Yat-sen University Cancer Center, Guangzhou

  Registry updated 2026-07-22

• NCT07409428

  A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

  Trial Treatment · Phase 3 · Hutchmed

  Baoding NO.1 Central Hospital, Baoding · Beijing Tongren Hospital, Capital Medical University, Beijing · Beijing GoBroad Hospital, Beijing · The First Affiliated Hospital of Bengbu Medical College, Bengbu · The First Hospital of Jilin University, Changchun · Hunan Cancer Hospital, Changsha · People's Hospital of Hunan Province, Changsha · The Second Xiangya Hospital of Central South University, Changsha · West China Hospital of Sichuan University, Chengdu · Sichuan Provincial People's Hospital, Chengdu · The First Affiliated Hospital of Chongqing Medical University, Chongqing · Chongqing University Cancer Hospital, Chongqing · Quanzhou First Hospital.Fujian, Fujian · Fujian Medical University Union Hospital, Fuzhou · Sun Yat-sen University Cancer Center, Guangzhou · Guangdong Provincial People's Hospital, Guangzhou · ZhuJiang Hospital of Southern Medical University（The Second Clinical Medical College）, Guangzhou · The Affiliated Hospital of Guizhou Medical University, Guiyang · Zhejiang Cancer Hospital, Hangzhou · The First Affiliated Hospital, Zhejiang University, Hangzhou · Harbin Medical University Cancer Hospital, Harbin · The Second Affiliated Hospital Of Anhui Medical University, Hefei · Shandong Cancer Hospital & institute, Jinan · Qilu Hospital of Shandong University, Jinan · The First Affiliated Hospital of Kunming Medical University, Kunming · Jiangxi Cancer Hospital, Nanchang · Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing · Jiangsu Cancer Hospital, Nanjing · The First Affiliated Hospital of Guangxi Medical University, Nanning · The Affiliated Hospital of Qingdao University, Qingdao · Tongji Hospital of Tongji University, Shanghai · Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai · Fudan University Shanghai Cancer Center, Shanghai · Shengjing Hospital Of China Medical University, Shenyang · Shenzhen People's Hospital, Shenzhen · Shanxi Provincial Cancer Hospital, Taiyuan · North China University of Science and Technology Affiliated Hospital, Tangshan · Tianjin People's Hospital, Tianjin · Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin · Tianjin Medical University Cancer Institute & Hospital, Tianjin · People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi · The First Affiliated Hospital of WMU, Wenzhou · Wuhan Union Hospital of China, Wuhan · Hubei Cancer Hospital, Wuhan · The First Affiliated hospital of Xiamen University, Xiamen · The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal), Xi'an · The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an · The affiliated hospital of xuzhou medical university, Xuzhou · The First Affiliated Hospital of Zhengzhou University, Zhengzhou · Henan Cancer Hospital, Zhengzhou

  Registry updated 2026-07-20

• NCT07599423

  A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  Trial Treatment · Phase 2 · The First Affiliated Hospital of Soochow University

  The First Affiliated Hospital of Soochow University, Suzhou

  Registry updated 2026-07-13

• NCT07680933

  Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)

  Trial Treatment · Phase 2 · The Affiliated Hospital of Xuzhou Medical University

  The affiliated hospital of xuzhou medical university, Xuzhou

  Registry updated 2026-07-02

• NCT07677813

  Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma

  Trial Treatment · Phase 2 · Ou Bai, MD/PHD

  The First Bethune Hospital of Jilin University, Changchun

  Registry updated 2026-07-01

• NCT07669194

  Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  Research · Second Affiliated Hospital, Zhejiang University, School of Medicine

  Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

  Registry updated 2026-06-25

• NCT07507318

  Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission

  Trial Treatment · Phase 2 · Rong Tao

  Fudan University Shanghai Cancer Center, Shanghai

  Registry updated 2026-06-18

• NCT06594640

  R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

  Trial Treatment · Phase 1/2 · Institute of Hematology & Blood Diseases Hospital, China

  Institute of hematology&blood disease hospital, Tianjin

  Registry updated 2026-06-10

• NCT07608978

  Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes

  Trial Treatment · Phase 2 · The First Affiliated Hospital with Nanjing Medical University

  Jiangsu Province Hospital, Nanjing

  Registry updated 2026-05-27

• NCT07601607

  Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma

  Trial Treatment · Phase 1/2 · Sun Yat-sen University

  Sun Yat-sen University Cancer Center, Guangzhou

  Registry updated 2026-05-22

• NCT06005870

  Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression

  Trial Treatment · Phase 2 · Huazhong University of Science and Technology

  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

  Registry updated 2026-05-18

• NCT06867536

  Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden

  Trial Treatment · Phase 2 · Liling Zhang

  Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

  Registry updated 2026-05-15

• NCT07583771

  A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma

  Trial Treatment · Phase 1 · Chipscreen Biosciences, Ltd.

  Fudan University Shanghai Cancer Center, Shanghai

  Registry updated 2026-05-13

• NCT05018520

  The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk

  Trial Treatment · Phase 3 · Ruijin Hospital

  Ruijin hospital, Shanghai

  Registry updated 2026-05-11

• NCT07548697

  A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma

  Trial Treatment · Early phase 1 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

  Registry updated 2026-04-23

• NCT07523737

  Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

  Trial Treatment · Phase 2 · Beijing Tongren Hospital

  Beijing Tongren Hospital, Capital Medical University, Beijing

  Registry updated 2026-04-15

• NCT07511114

  A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping

  Trial Treatment · Phase 3 · Ruijin Hospital

  No. 197 Ruijin 2nd Road, Huangpu District, Shanghai, Shanghai, Shanghai, Shanghai

  Registry updated 2026-04-06

• NCT05257018

  R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse

  Trial Treatment · Phase 2 · Fudan University

  Dongmei Ji, Shanghai · Cancer Hospital affilicaited to Xinjiang Medical University, Ürümqi

  Registry updated 2026-04-02

• NCT07059650

  DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

  Trial Treatment · Phase 1/2 · Dizal Pharmaceuticals

  Peking University Third Hospital, Beijing · Hunan Cancer Hospital, Changsha · West China Hospital of Sichuan University, Chengdu · Zhujiang Hospital of Southern Medical University, Guangzhou · Sun Yat-sen University Cancer Center, Guangzhou · Guangdong Provincial People's Hospital, Guangzhou · The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou · Anhui Provincial Cancer Hospital, Hefei · LinYi Cancer Hospital, Linyi · Shanxi Cancer hospital, Taiyuan · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan · The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an · Henan Cancer Hospital, Zhengzhou

  Registry updated 2026-04-01

• NCT07499271

  Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

  Trial Treatment · Phase 2 · The First Affiliated Hospital of Soochow University

  The First Affiliated Hospital of Soochow University, Suzhou

  Registry updated 2026-03-30

All Diffuse large B-cell lymphoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error